Astrazeneca PLC (AZN) Rating Reiterated by Barclays PLC
Astrazeneca PLC (NYSE:AZN)‘s stock had its “overweight” rating reiterated by analysts at Barclays PLC in a research report issued on Thursday.
A number of other brokerages have also recently commented on AZN. Leerink Swann restated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Astrazeneca PLC in a research note on Wednesday, May 17th. UBS AG cut shares of Astrazeneca PLC from a “buy” rating to a “neutral” rating and dropped their price target for the company from $35.44 to $25.55 in a research note on Wednesday, April 5th. Jefferies Group LLC restated a “hold” rating on shares of Astrazeneca PLC in a research note on Monday, April 10th. BidaskClub cut shares of Astrazeneca PLC from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, Credit Suisse Group upgraded shares of Astrazeneca PLC from an “underperform” rating to a “neutral” rating in a research note on Friday, May 12th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $34.13.
Astrazeneca PLC (AZN) opened at 33.87 on Thursday. The stock’s 50 day moving average is $34.36 and its 200 day moving average is $30.51. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60. The company has a market capitalization of $85.76 billion, a PE ratio of 25.37 and a beta of 0.77.
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, April 27th. The company reported $0.99 EPS for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.61. The company had revenue of $5.41 billion for the quarter, compared to analysts’ expectations of $5.40 billion. Astrazeneca PLC had a net margin of 15.21% and a return on equity of 35.65%. Astrazeneca PLC’s revenue was down 11.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.95 EPS. On average, analysts anticipate that Astrazeneca PLC will post $1.86 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.watchlistnews.com/astrazeneca-plc-azn-rating-reiterated-by-barclays-plc/1444389.html.
Institutional investors have recently modified their holdings of the company. OLD National Bancorp IN bought a new position in shares of Astrazeneca PLC during the second quarter worth approximately $201,000. Eqis Capital Management Inc. raised its position in Astrazeneca PLC by 16.5% in the second quarter. Eqis Capital Management Inc. now owns 19,738 shares of the company’s stock valued at $673,000 after buying an additional 2,796 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Astrazeneca PLC during the second quarter valued at approximately $105,000. Fisher Asset Management LLC raised its position in Astrazeneca PLC by 476.9% in the second quarter. Fisher Asset Management LLC now owns 11,081,856 shares of the company’s stock valued at $377,780,000 after buying an additional 9,160,764 shares in the last quarter. Finally, NEXT Financial Group Inc raised its position in Astrazeneca PLC by 1.8% in the second quarter. NEXT Financial Group Inc now owns 6,463 shares of the company’s stock valued at $220,000 after buying an additional 115 shares in the last quarter. 14.01% of the stock is currently owned by hedge funds and other institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.